Navigation Links
New phase II study supports potential of gs-9450 as new treatment option for steatohepatitis
Date:4/16/2010

Vienna, Austria, Thursday 15 April: Results from a multinational phase II study presented today at the International Liver CongressTM 2010 have shown that treatment with the caspase inhibitor GS-9450 can reduce markers of liver damage in patients with non-alcoholic steatohepatitis (NASH the most serious form of non-alcoholic liver disease) as demonstrated by reduced levels of alanine (ALT) and aspartate aminotransferases (AST), hepatic enzymes that indicate cell damage.

GS-9450, a potent inhibitor of caspases-8, -9 and -1, the intra-cellular proteins that initiate programmed cell death (or cell suicide, also known as apoptosis) in damaged cells, is a potential new treatment option for patients with NASH a disease characterised by fat build-up in liver cells with subsequent inflammation resulting in accumulation of scar tissue (fibrosis), cirrhosis and eventual liver failure.

Professor Fabio Marra of the EASL scientific committee commented: "It is encouraging to see that GS-9450-associated reduction of apoptosis and cell damage seen in animal models has translated to a significant patient population, and seems to be consistent with a good tolerability profile in patients from a variety of countries. Further studies are needed to evaluate the action of this therapy on histology and to confirm the drug's efficacy and safety in larger patient populations."

In this double-blind, parallel-group study, patients (n=124, principally male, mean age 45 years, with Body Mass Index (BMI) of >30kg/m2) with biopsy-proven NASH were randomised to receive 1, 5, 10 or 40mg GS-9450 or placebo once daily for 4 weeks. After 4 weeks on treatment, patients in the 40mg treatment group experienced the greatest reduction in ALT and AST levels.

At week four, linear regression of ALT versus GS-9450 dose was highly significant (p<0.0001) with 35% achieving ALT levels within the normal range (7-56 U/L ) compared to 0% at study baseline, and 48% achiev
'/>"/>

Contact: Isabelle Scali
media.easl2010@cohnwolfe.com
44-771-743-5103
European Association for the Study of the Liver
Source:Eurekalert

Page: 1 2

Related medicine news :

1. NASA selects DNA Medicine Institutes Nanoscale Diagnostics Technology for Phase II SBIR
2. PRA International Rolls out Client Access to Oracle(R) RDC for Early Phase Studies
3. Treatment for chronic hepatitis C: A phase II study
4. New Pixantrone Phase III Data to be Presented at the 51st Annual Meeting of the American Society of Hematology
5. InstaMed Achieves Core Phase II Certification to Streamline Provider Access to Consistent Electronic Eligibility and Claim Status
6. Pharmacyclics, Inc. Announces Presentation of Interim Results From Phase I Trial of Its First-In-Human Btk Inhibitor PCI-32765
7. Aetna and WellPoint Achieve CORE Phase II Certification
8. Data from Phase 1 Study Confirm High Response Rate of Micromets Blinatumomab in Patients with Non-Hodgkins Lymphoma
9. Pharmacyclics, Inc. Reports Interim Safety and Clinical Data from a Phase I/II Clinical Trial of its Oral HDAC Inhibitor PCI-24781 in Lymphoma at the American Society of Hematology Annual Meeting
10. Hepregen Corporation Receives SBIR Phase II Grant from the National Science Foundation and Presents Corporate Update at OneMed Forum
11. Synomics Pharma and Bioscience Laboratories Announce Partnership to Provide Topical Clinical Phase 1 Study Services
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:7/22/2014)... July 22, 2014 The European Bio ... market in Europe with analysis and forecast of revenue. ... grow from around $528.5 million in 2013 to $940.6 ... 2013 to 2018. , Browse through the TOC of ... idea of the in-depth analysis provided. , http://www.micromarketmonitor.com/market/europe-bio-stimulants-1315565884.html ...
(Date:7/22/2014)... Colorado Springs, CO (PRWEB) July 22, 2014 ... (ASTI), the leader in professional data archiving solutions, ... Cloud-Integrated Storage (CiS) data archiving solution. The ... cloud supporting the company’s focus on compliant data ... enforcement, and more. , The introduction of ...
(Date:7/22/2014)... the University of Murcia have studied the changes ... a personality trait that causes difficulties in inhibiting ... and leads to unplanned actions without considering the ... indicator for predicting the risk of behavioural problems. ... the University of Murcia analyses whether the connectivity ...
(Date:7/22/2014)... There’s an old adage that says ... new improvements and enhancements Global Eyeglasses has made, people ... lasting impressions while having what they need to sport ... , “We are offering new sports clip prescription sunglasses ... Sagar, CEO of Global Eyeglasses . , ...
(Date:7/22/2014)... York, NY (PRWEB) July 22, 2014 ... the Icahn School of Medicine at Mount Sinai have ... associated with the risk of developing schizophrenia, in the ... date, conducted with 80,000 people. The findings, published online ... may underlie schizophrenia, and could lead to new approaches ...
Breaking Medicine News(10 mins):Health News:Europe Bio Stimulants Market is Expected to Reach $940.6 Million in 2018 - New Report by MicroMarket Monitor 2Health News:Europe Bio Stimulants Market is Expected to Reach $940.6 Million in 2018 - New Report by MicroMarket Monitor 3Health News:Europe Bio Stimulants Market is Expected to Reach $940.6 Million in 2018 - New Report by MicroMarket Monitor 4Health News:Europe Bio Stimulants Market is Expected to Reach $940.6 Million in 2018 - New Report by MicroMarket Monitor 5Health News:Data Archiving Leader Alliance Storage Technologies Releases Enterprise Class Cloud-Integrated Storage Solution 2Health News:Data Archiving Leader Alliance Storage Technologies Releases Enterprise Class Cloud-Integrated Storage Solution 3Health News:Data Archiving Leader Alliance Storage Technologies Releases Enterprise Class Cloud-Integrated Storage Solution 4Health News:Children's impulsive behaviour is related to their brain connectivity 2Health News:Global Eyeglasses Adds New Products and Enhances Services 2Health News:Mount Sinai Scientists and International Team Shed New Light on Schizophrenia in Largest Genomic Study Published to Date 2Health News:Mount Sinai Scientists and International Team Shed New Light on Schizophrenia in Largest Genomic Study Published to Date 3Health News:Mount Sinai Scientists and International Team Shed New Light on Schizophrenia in Largest Genomic Study Published to Date 4
... in Afghanistan are increasingly suffering from war–related anxiety and ... ,Ontario’s ombudsman Andre Marin had undertaken a recent ... center for treatment of such traumatized children was caught ... bodies unwilling to take financial responsibilities. ,Mr. ...
... All India Institute of Medical Sciences (AIIMS) Director P. ... a former patient alleging// that the state-run hospital had ... undergoing treatment at its cardiac and neuro center. ... to Venugopal, Mayank Sharma, former senior financial advisor, Arti ...
... scientists have undertaken what is described as the biggest DNA ... mark the biggest single leap in the understanding of how ... to a new wave of tailored therapies and tests to ... ,A coalition of 50 groups, including 24 leading ...
... human interference may destroy much of Sundarbans in India and ... a new UNESCOreport.// ,"Sea-level rise is the greatest ... Asia. A 45 cm rise in global sea levels would ... mangroves," the report warned. ,The report, "Case Studies ...
... may be at far higher risk for eating disorders ... first population-based study of its kind, the// researchers found ... eating disorders. ,Researchers Ilan H. ... the Mailman School of Public Health and principal investigator, ...
... remains the most beneficial proven intervention for ischemic stroke, ... Guidelines for the Early Management of Adults with Ischemic ... intra-arterial administration of clot-busting drugs and mechanical removal of ... guidelines focus on the crucial first hours from the ...
Cached Medicine News:Health News:Collateral Damage-Children Of Canadian Soldiers Suffer 2Health News:Court Issues Notice to Venugopal Over Fund Irregularities 2Health News:UK Scientists to Reveal Genetic Secrets Behind Serious Illnesses 2Health News:Climate Change Threatens Sundarbans and World Heritage Sites 2Health News:Climate Change Threatens Sundarbans and World Heritage Sites 3Health News:Eating Disorders Highly Prevalent Among Gay and Bisexual Men 2Health News:Intravenous Delivery of Clot-busting Drug Still Best Intervention for Ischemic Stroke 2
(Date:7/22/2014)... , July 22, 2014 The steady ... is spreading to previously rep-friendly specialties, according to ... and marketing consulting firm ZS Associates.      ... 200 U.S. pharmaceutical sales teams. The report examines ... meet with the pharmaceutical sales reps who visit ...
(Date:7/22/2014)... 22, 2014 BioDelivery Sciences International, Inc. (BDSI) ... of Directors has appointed Charles J. (Chuck) Bramlage ... members of the Board.  Mr. Bramlage ... in marketing, sales and other commercial functions.  He is ... a development stage company that was recently acquired by ...
(Date:7/22/2014)... 22, 2014  UL (Underwriters Laboratories), a global ... Food and Drug Administration (FDA) has recognized two ... medical devices incorporating lithium or nickel-based batteries. The ... Household and Commercial Batteries, and UL 1642 - ... Consensus standards are standards recognized by the FDA ...
Breaking Medicine Technology:Even traditionally rep-friendly specialists will see fewer pharmaceutical sales reps this year, according to ZS Associates 2Even traditionally rep-friendly specialists will see fewer pharmaceutical sales reps this year, according to ZS Associates 3Even traditionally rep-friendly specialists will see fewer pharmaceutical sales reps this year, according to ZS Associates 4Even traditionally rep-friendly specialists will see fewer pharmaceutical sales reps this year, according to ZS Associates 5BioDelivery Sciences Appoints Charles J. Bramlage and Dr. Barry I. Feinberg to its Board of Directors 2BioDelivery Sciences Appoints Charles J. Bramlage and Dr. Barry I. Feinberg to its Board of Directors 3BioDelivery Sciences Appoints Charles J. Bramlage and Dr. Barry I. Feinberg to its Board of Directors 4BioDelivery Sciences Appoints Charles J. Bramlage and Dr. Barry I. Feinberg to its Board of Directors 5BioDelivery Sciences Appoints Charles J. Bramlage and Dr. Barry I. Feinberg to its Board of Directors 6BioDelivery Sciences Appoints Charles J. Bramlage and Dr. Barry I. Feinberg to its Board of Directors 7Two UL Battery Safety Standards Are now FDA Recognized Consensus Standards for Medical Devices 2
... , RYE, N.Y., Oct. 14 Curemark, LLC, a drug ... diseases, announced that it has enrolled the first patients in ... The first clinical trial patients have been enrolled at Lake ... trial sites with a total 170 children across the country. ...
... Inc. (Nasdaq: VSCP ), a leading provider of quantitative ... the company,s chief business and financial officer, will be presenting ... Bio Investor Forum in San Francisco, California. Ms. Henderson is ... October 29, 2009 at the Palace Hotel, San Francisco. , ...
Cached Medicine Technology:Curemark Enrolls First Patients in Phase III Clinical Trials for Autism Treatment 2VirtualScopics to Present at the 8th Annual Bio Investor Forum 2
The only daily cleaner specially formulated with isopropyl alcohol to help dissolve lipids and oil-based make-up from contact lenses....
Clerz Plus helps retain moisture to relieve dryness and removes protein buildup from your lenses while you wear them for longer wear comfort....
Lens Plus rewetting drops for soft contact lenses....
... Renu Multiplus preservative free lubricating ... moisturize your eyes while you're ... gentle preservative free formula is ... be sensitive to preservatives and ...
Medicine Products: